Innovent

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1801)

INSIDE INFORMATION ANNOUNCEMENT PRODUCT REVENUE IN THE FIRST HALF AND THE SECOND QUARTER OF 2026

This announcement is made by Innovent Biologics, Inc. (the "**Company**" or "**Innovent**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

For the first half of 2026, the total product revenue of the Company amounted to over RMB8.2 billion, representing a robust year-over-year growth of over 55%. Notably, the total product revenue in the second quarter of 2026 amounted to over RMB4.3 billion, representing a robust year-over-year growth of approximately 60%. This outstanding performance reflects the continued successful execution of our dual-engine growth strategy. Our general biomedicine business sustained exceptional growth, with flagship products including mazdutide, SINTBILO® (tafolecimab injection) and SYCUME® (teprotumumab N01 injection) delivering strong commercial performance and collectively becoming a major revenue diver. Meanwhile, our oncology leadership remains strong, as the five tyrosine kinase inhibitor (TKI) therapies newly included in the National Reimbursement Drug List (NRDL) continued to gain broad market penetration and became an increasingly meaningful contributor to revenue. In addition, through the collaboration with Eli Lilly and Company ("**Lilly**") for Verzenios® (abemaciclib) in mainland China, the Company is also strategically expanding our commercial footprint into breast cancer, further reinforcing the foundation for pipeline development and market expansion in this franchise.

In the first half of 2026, the Company further strengthened its position as a leading biopharmaceutical company in China, supported by industry-leading revenue scale and strong growth across a diversified product portfolio. On global innovation, we are advancing three core innovative assets into global Phase 3 clinical trials, while continuing to expand our next-generation pipeline across oncology, cardiovascular and metabolism (CVM), autoimmune diseases and ophthalmology. Meanwhile, the Company's innovation capabilities have been increasingly validated through more than 20 collaborated programs – among which five are co-development and co-commercialization (Co-Co) programs – with leading multinational pharmaceutical companies including Pfizer, Lilly, Takeda and Roche. Looking ahead, Innovent will continue to leverage the expansion of its domestic business and advancement of its global innovation pipeline to accelerate its international expansion, steadily progressing toward its long-term vision of becoming a world-class biopharmaceutical company.

The financial information set out in this announcement was prepared based on internal management records of the Group which have not been audited or reviewed by external auditors, and as such, the data is for investors' information only. Such data may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company (including but not limited to those published on an annual or semi-annual basis), due to various uncertainties during the process of collection and collating of such data. This announcement does not constitute, nor should it be construed as, an offer or solicitation for the purchase or sale of any securities or financial instruments of the Group.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China,
August 5, 2026

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as Executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Mr. Shuyun Chen and Dr. Stephen A. Sherwin as Independent Non-executive Directors.